/EFTR
EFTR Stock - eFFECTOR Therapeutics, Inc.
Healthcare|BiotechnologyOTC
$0.00+0.00%
+$0.00 (+0.00%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.16
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.81
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+2749900.0%upside
Target: $5.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EFTR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$5.50
STOP LOSS$0.00
RISK/REWARD1:27499.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.98
52W High$0.00
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | $3.55M | $1.43M | $42.00M | N/A |
| Gross Profit | $-111,000 | $3.50M | $1.41M | $42.00M | $-307,000 |
| Gross Margin | N/A | 98.5% | 98.3% | 100.0% | N/A |
| Operating Income | $-33,844,000 | $-32,403,000 | $-33,327,000 | $15.82M | $-28,605,000 |
| Net Income | $-35,811,000 | $-12,927,000 | $15.80M | $14.21M | $-29,739,000 |
| Net Margin | N/A | -363.8% | 1104.8% | 33.8% | N/A |
| EPS | $-16.37 | $-7.85 | $9.78 | $0.28 | $-539.08 |
Company Overview
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
EFTRBeat Rate
64%
Last 11 quarters
Avg Surprise
+62.1%
EPS vs Estimate
Beats / Misses
7/3
1 met exactly
Latest EPS
$-2.16
Q2 2024
EPS Surprise History
Q3 22
+5.6%
$-4.25vs$-4.50
Q4 22
+14.8%
$-5.75vs$-6.75
Q1 23
-22.2%
$-5.50vs$-4.50
Q2 23
-9.1%
$-6.00vs$-5.50
Q3 23
+10.5%
$-4.25vs$-4.75
Q4 23
0.0%
$-3.25vs$-3.25
Q1 24
-25.3%
$-3.42vs$-2.73
Q2 24
+0.5%
$-2.16vs$-2.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 27, 2025 | — | — | — | — |
Q3 2025 | Aug 7, 2025 | — | — | — | — |
Q2 2025 | May 30, 2025 | $-2.02 | — | — | — |
Q1 2025 | Feb 28, 2025 | $-2.02 | — | — | — |
Q4 2024 | Nov 14, 2024 | — | — | — | — |
Q3 2024 | Aug 28, 2024 | $-2.02 | — | — | — |
Q2 2024 | May 9, 2024 | $-2.17 | $-2.16 | +0.5% | ✓ BEAT |
Q1 2024 | Mar 25, 2024 | $-2.73 | $-3.42 | -25.3% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-3.25 | $-3.25 | 0.0% | = MET |
Q3 2023 | Aug 8, 2023 | $-4.75 | $-4.25 | +10.5% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-5.50 | $-6.00 | -9.1% | ✗ MISS |
Q1 2023 | Mar 8, 2023 | $-4.50 | $-5.50 | -22.2% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-6.75 | $-5.75 | +14.8% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-4.50 | $-4.25 | +5.6% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-8.00 | $1.75 | +121.9% | ✓ BEAT |
Q1 2022 | Mar 16, 2022 | $-6.25 | $11.00 | +276.0% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.20 | $0.42 | +310.0% | ✓ BEAT |
Q3 2021 | Aug 31, 2021 | — | $-6.15 | — | — |
Q2 2021 | Jun 3, 2021 | — | $-11.00 | — | — |
Q1 2021 | Mar 29, 2021 | — | $-0.66 | — | — |
Latest News
Loading news...
Frequently Asked Questions about EFTR
What is EFTR's current stock price?
eFFECTOR Therapeutics, Inc. (EFTR) is currently trading at $0.00 per share. The stock has moved +0.00% today.
What is the analyst price target for EFTR?
The average analyst price target for EFTR is $5.50, based on 1 analyst.
What sector is eFFECTOR Therapeutics, Inc. in?
eFFECTOR Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is EFTR's market cap?
eFFECTOR Therapeutics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does EFTR pay dividends?
No, eFFECTOR Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADYX
Adynxx, Inc.
$0.00
Mkt Cap: $0.0B
ATRX
Adhera Therapeutics, Inc.
$0.00
Mkt Cap: $0.0B
CFRXQ
ContraFect Corporation
$0.00
Mkt Cap: $0.0B
DMKPQ
DMK Pharmaceuticals Corporation
$0.00
Mkt Cap: $0.0B
IMVIF
IMV Inc.
$0.00
Mkt Cap: $0.0B
LITH
BioELife Corp.
$0.00
Mkt Cap: $0.0B
OMMH
Omnimmune Holdings, Inc.
$0.00
Mkt Cap: $0.0B
ONCSQ
OncoSec Medical Incorporated
$0.00
Mkt Cap: $0.0B
PROT
Proteonomix, Inc.
$0.00
Mkt Cap: $0.0B
UTRS
Minerva Surgical, Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to EFTR for comparison